LYRA
Lyra Therapeutics Inc
NASDAQ · Pharmaceuticals
$1.82
+0.05 (+2.82%)
Open$1.71
Previous Close$1.77
Day High$1.90
Day Low$1.71
52W High$15.05
52W Low$10.10
Volume—
Avg Volume603.0K
Market Cap3.23M
P/E Ratio20.68
EPS$0.57
SectorPharmaceuticals
Analyst Ratings
Sell
9 analysts
Price Target
+669.2% upside
Current
$1.82
$1.82
Target
$14.00
$14.00
$9.32
$14.00 avg
$16.42
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 655.7K | 681.7K | 558.5K |
| Net Income | 178.6K | 169.3K | 107.5K |
| Profit Margin | 27.2% | 24.8% | 19.3% |
| EBITDA | 306.3K | 337.6K | 271.6K |
| Free Cash Flow | 107.5K | 110.0K | 71.2K |
| Rev Growth | +5.2% | +3.7% | -9.4% |
| Debt/Equity | 0.60 | 0.67 | 0.68 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,058.18 | +3.66% | 48.5 | 1.00T |
| JNJ | Johnson & Johnson | $239.99 | +0.93% | 21.6 | 578.21B |
| MRK | Merck & Co. Inc. | $121.93 | +1.82% | 16.6 | 302.63B |
| PFE | Pfizer Inc. | $27.22 | +2.76% | 19.9 | 154.76B |
| BMY | Bristol-Myers Squibb Co | $61.99 | +4.15% | 17.9 | 126.20B |
| ZTS | Zoetis Inc | $127.42 | +0.54% | 21.5 | 56.95B |